Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in p

[News]

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

More... (http://www.news-medical.net/news/20100512/Quest-initiates-dosing-in-Phase-I-clinical-trial-with-SL052-Photodynamic-Therapy-in-prostate-cancer-patients.aspx)